|
JPS54109983A
(en)
*
|
1978-02-13 |
1979-08-29 |
Sumitomo Chem Co Ltd |
Novel spiroamine derivative and its preparation
|
|
EP0450761A1
(en)
|
1990-03-02 |
1991-10-09 |
Merck & Co. Inc. |
Spirocyclic oxytocin antagonists
|
|
CA2037357A1
(en)
|
1990-03-02 |
1991-09-03 |
Ben E. Evans |
Methods for using spirocyclic oxytocin antagonists
|
|
US5731317A
(en)
|
1995-03-10 |
1998-03-24 |
Merck & Co., Inc. |
Bridged piperidines promote release of growth hormone
|
|
US6013652A
(en)
|
1997-12-04 |
2000-01-11 |
Merck & Co., Inc. |
Spiro-substituted azacycles as neurokinin antagonists
|
|
US6916822B2
(en)
|
2000-02-18 |
2005-07-12 |
Meiji Seika Kaisha, Ltd. |
Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
|
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US7504506B2
(en)
|
2003-11-04 |
2009-03-17 |
Elixir Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
TWI350168B
(en)
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
|
CA2599925A1
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
|
EP2316829A1
(en)
|
2005-12-21 |
2011-05-04 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic derivatives as modulators of ion channels
|
|
EP2023924B1
(en)
|
2006-05-18 |
2016-08-03 |
Merck Sharp & Dohme Corp. |
Aryl-fused spirocyclic compounds
|
|
EP2027106A2
(en)
|
2006-06-13 |
2009-02-25 |
Vertex Pharmaceuticals Incorporated |
Cgrp receptor antagonists
|
|
US8163737B2
(en)
|
2006-06-13 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
|
US7834000B2
(en)
|
2006-06-13 |
2010-11-16 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
|
US20080306102A1
(en)
|
2007-05-18 |
2008-12-11 |
Kowa Co., Ltd. |
Novel spirooxyindole compounds and drugs containing same
|
|
WO2009061676A2
(en)
|
2007-11-06 |
2009-05-14 |
Amira Pharmaceuticals, Inc. |
Antagonists of pgd2 receptors
|
|
JP5451646B2
(ja)
|
2008-02-27 |
2014-03-26 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
|
|
US8143403B2
(en)
|
2008-04-11 |
2012-03-27 |
Bristol-Myers Squibb Company |
CGRP receptor antagonists
|
|
CA2779958A1
(en)
|
2008-11-06 |
2010-05-14 |
University Of Miami |
Role of soluble upar in the pathogenesis of proteinuric kidney disease
|
|
MX2011009571A
(es)
|
2009-03-13 |
2011-10-19 |
Boehringer Ingelheim Int |
Inhibidores de beta-secretasa.
|
|
US8288431B2
(en)
*
|
2010-02-17 |
2012-10-16 |
Hoffmann-La Roche Inc. |
Substituted spiroindolinones
|
|
US9023355B2
(en)
|
2010-04-13 |
2015-05-05 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for treating renal disease
|
|
CN101851237B
(zh)
|
2010-06-18 |
2012-10-17 |
南方医科大学 |
一种螺环化合物及其制备方法和应用
|
|
MX2013009393A
(es)
|
2011-02-18 |
2013-08-29 |
Vertex Pharma |
Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
|
|
CN102516263B
(zh)
|
2011-10-25 |
2015-04-08 |
南方医科大学 |
一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
|
|
US10130632B2
(en)
|
2012-11-27 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
|
WO2016022644A1
(en)
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
WO2016071293A2
(en)
|
2014-11-03 |
2016-05-12 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
TW201718010A
(zh)
|
2015-06-19 |
2017-06-01 |
健臻公司 |
治療原發性局部節段性腎小球硬化症之方法
|
|
CN110621316B
(zh)
|
2017-04-21 |
2024-01-26 |
Epizyme股份有限公司 |
用ehmt2抑制剂进行的组合疗法
|
|
WO2019115586A1
(en)
|
2017-12-12 |
2019-06-20 |
Phenex Discovery Verwaltungs-GmbH |
Oxalamides as modulators of indoleamine 2,3-dioxygenase
|
|
IL278785B2
(en)
|
2018-05-22 |
2025-03-01 |
Ionis Pharmaceuticals Inc |
Modulators of apol1 expression
|
|
US11618746B2
(en)
*
|
2018-12-17 |
2023-04-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of APOL1 and methods of using same
|
|
IL286481B2
(en)
|
2019-03-20 |
2025-12-01 |
Goldfinch Bio Inc |
Pyridazinones and methods of use thereof
|
|
EP3960736A4
(en)
|
2019-04-26 |
2023-04-19 |
Generos Biopharma Ltd. |
HETEROCYCLIC COMPOUND, ITS APPLICATION AND COMPOSITION WITH IT
|
|
KR20220118527A
(ko)
|
2019-12-23 |
2022-08-25 |
제넨테크, 인크. |
아포지질단백질 l1-특이적 항체 및 이용 방법
|
|
TW202140480A
(zh)
|
2020-01-15 |
2021-11-01 |
日商拉夸里亞創藥股份有限公司 |
作為crhr2拮抗劑之螺雜環衍生物
|
|
WO2021154997A1
(en)
|
2020-01-29 |
2021-08-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
US20210246121A1
(en)
|
2020-02-04 |
2021-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitor and methods of using same
|
|
IL296035A
(en)
|
2020-03-06 |
2022-10-01 |
Vertex Pharma |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
JP2023524563A
(ja)
|
2020-05-07 |
2023-06-12 |
ラムバム メド－テック リミテッド |
Ａｐｏｌ１－関連疾患の治療に使用するための組成物
|
|
CN115867532A
(zh)
|
2020-06-12 |
2023-03-28 |
弗特克斯药品有限公司 |
Apol1的抑制剂及其用途
|
|
CN115867543A
(zh)
|
2020-06-12 |
2023-03-28 |
弗特克斯药品有限公司 |
Apol1抑制剂的固体形式及其使用方法
|
|
CA3185604A1
(en)
*
|
2020-06-12 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and use of the same
|
|
CN116547287B
(zh)
|
2020-08-26 |
2025-09-26 |
弗特克斯药品有限公司 |
Apol1的抑制剂及其使用方法
|
|
IL301574A
(en)
|
2020-09-25 |
2023-05-01 |
Neuropore Therapies Inc |
Modulators of tlr signaling modulator compounds, compositions comprising same and uses thereof
|
|
KR20230110544A
(ko)
|
2020-11-19 |
2023-07-24 |
머크 샤프 앤드 돔 엘엘씨 |
혈장 칼리크레인 억제제
|
|
US20250197396A1
(en)
|
2020-12-07 |
2025-06-19 |
Lieber Institute, Inc. |
Compounds for inhibiting inositol hexakisphosphate kinase (ip6k) and methods of use thereof
|
|
CN116997546A
(zh)
|
2021-02-19 |
2023-11-03 |
梅兹治疗公司 |
Apol1抑制剂及使用方法
|
|
EP4351569A4
(en)
|
2021-05-28 |
2025-04-16 |
D.E. Shaw Research, LLC |
Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
|
|
US20230119114A1
(en)
|
2021-08-26 |
2023-04-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitors and methods of using same
|
|
AR127625A1
(es)
|
2021-11-10 |
2024-02-14 |
Nurix Therapeutics Inc |
Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos
|
|
WO2023091561A1
(en)
|
2021-11-18 |
2023-05-25 |
Enanta Pharmaceuticals, Inc. |
Novel spiropyrrolidine derived antiviral agents
|
|
EP4440697A1
(en)
*
|
2021-11-30 |
2024-10-09 |
Vertex Pharmaceuticals Incorporated |
Spirocyclic inhibitors of apol1 and methods of using same
|
|
US12612379B2
(en)
|
2021-11-30 |
2026-04-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of APOL1 and methods of using same
|
|
MX2024008868A
(es)
|
2022-01-18 |
2024-09-23 |
Maze Therapeutics Inc |
Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
|
|
CN118946349A
(zh)
*
|
2022-01-18 |
2024-11-12 |
梅兹治疗公司 |
Apol1抑制剂及使用方法
|
|
CR20240344A
(es)
*
|
2022-01-18 |
2024-12-09 |
Maze Therapeutics Inc |
Inhibidores de apol1 y métodos de uso
|
|
CN119212986A
(zh)
|
2022-02-08 |
2024-12-27 |
弗特克斯药品有限公司 |
作为apol1的抑制剂的螺哌啶衍生物及其使用方法
|
|
AU2023219516A1
(en)
|
2022-02-08 |
2024-08-22 |
Vertex Pharmaceuticals Incorporated |
2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
|
|
EP4476228A1
(en)
|
2022-02-08 |
2024-12-18 |
Vertex Pharmaceuticals Incorporated |
4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
|
|
CA3251050A1
(en)
*
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
|
|
CN119731179A
(zh)
|
2022-03-25 |
2025-03-28 |
密歇根大学董事会 |
Ikzf2降解剂及其用途
|
|
WO2023194895A1
(en)
|
2022-04-06 |
2023-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Pyrrol derivatives as inhibitors of apolipoprotein l-1
|
|
WO2024249254A2
(en)
|
2023-05-26 |
2024-12-05 |
Maze Therapeutics, Inc. |
Methods of using apol1 inhibitors
|
|
CN121793963A
(zh)
|
2023-07-11 |
2026-04-03 |
梅兹治疗公司 |
Apol1抑制剂和使用方法
|
|
WO2025015106A2
(en)
|
2023-07-11 |
2025-01-16 |
Maze Therapeutics, Inc. |
Apol1 inhibitors and methods of use thereof
|
|
WO2025019479A1
(en)
|
2023-07-17 |
2025-01-23 |
Maze Therapeutics, Inc. |
Apol1 inhibitors and methods of use
|